RE:How many new products does it take…I believe the market needs to see more QAPS deals.
I re-read Bruce Krugels last report just the other day. At this time the consensus seemed to be almost $10 million of VTM sales per year........not zero.
The Kinlytic deal, while very good, and exciting is still a few years off before it is material (IMO)
The Antigen business is increasing but it is the lowest margin of their business units.
Until then I think the share price reacts to profitability and material QAPS deals.
I am not saying these things wont occur, or that the Kinlytic deal is anything but exciting.
I am only saying that in the short to medium term that new QAPS deals and record quarters is all the market is going to react to.